Remission in MDD: What Does the Future Hold for Clinicians and Patients?
Although many antidepressants are available to treat major depressive disorder (MDD), as many as 70% of patients diagnosed with MDD do not reach remission even after receiving an adequate course of treatment. Remission is currently being redefined. The outcome measure that is generally reported in clinical trials “has been arbitrarily defined as a symptom reduction of 50% or greater from pretreatment in total symptom severity.” Yet, a response that does not achieve an asymptomatic remitted state “constitutes an unsatisfactory outcome in that it includes patients with ongoing, clinically significant disease activity. While symptomatic remission increases the probability for recovery in MDD. Available evidence indicates that the majority of individuals with MDD receiving guideline-concordant and measurement-based care do not achieve and sustain a fully remitted state with index antidepressant treatment.
This neuroscienceCME Live and On Demand will challenge clinicians to reinvent the future of MDD treatment which includes increased patient participation in the treatment process, measurement-based care and a re-definition of treatment to remission as improvement of all symptoms of MDD with functional recovery.
Assess symptom severity with a validated tool at each visit.
Initiate an evidence-based treatment plan that involves patient participation to address residual symptoms of depression.
Develop a long-term treatment plan with the patient focused on sustained remission and recovery.
1.5 Free CEUs for Case Managers
This course also offers Free CEUs for Physicians and Pharmacists